By the end of last year Santhera Pharmaceuticals AG's stock price had lost more than half its value; it seems 2018 will not be kinder as the company's hopes of securing regulatory approval for a novel treatment for muscular dystrophy are set to be dashed again.
Santhera Braced For Another CHMP No In Duchenne
Santhera had a tumultuous 2017 and recovery is not going to be easy this year as its lead compound for the rare disease Duchenne muscular dystrophy is about to be rejected by regulators in Europe for a second time.
More from Rare Diseases
More from Scrip
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.